Oyster Point Pharma Past Earnings Performance
Past criteria checks 0/6
Key information
-45.9%
Earnings growth rate
35.9%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 91.7% |
Return on equity | n/a |
Net Margin | -902.0% |
Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Is Oyster Point Pharma (NASDAQ:OYST) Using Debt In A Risky Way?
Nov 08Oyster Point's nasal spray to be covered by largest Medicare pharmacy benefit manager
Aug 17Oyster Point Pharma, Inc. (NASDAQ:OYST) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 14Oyster Point stock rises 11% after H.C. Wainwright begins coverage with Buy rating
Jul 18Oyster Therapeutics: State Of Business Is Confounding
Jun 30Is Oyster Point Pharma (NASDAQ:OYST) Using Debt In A Risky Way?
Dec 24Oyster Point Pharma (NASDAQ:OYST) Is In A Good Position To Deliver On Growth Plans
Oct 15Oyster Point Pharma starts enrollment in mid-stage Neurotrophic Keratopathy study
Jun 21Here's Why We're Not Too Worried About Oyster Point Pharma's (NASDAQ:OYST) Cash Burn Situation
May 10Need To Know: Oyster Point Pharma, Inc. (NASDAQ:OYST) Insiders Have Been Buying Shares
Feb 09Oyster Point Pharma files US application for its lead program in dry eye disease
Dec 18Companies Like Oyster Point Pharma (NASDAQ:OYST) Are In A Position To Invest In Growth
Dec 18Oyster Point Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Revenue & Expenses BreakdownBeta
How Oyster Point Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 22 | 20 | -177 | 155 | 19 |
30 Jun 22 | 32 | -158 | 149 | 21 |
31 Mar 22 | 27 | -130 | 122 | 23 |
31 Dec 21 | 25 | -101 | 95 | 24 |
30 Sep 21 | 18 | -81 | 67 | 30 |
30 Jun 21 | 0 | -79 | 47 | 32 |
31 Mar 21 | 0 | -73 | 39 | 34 |
31 Dec 20 | 0 | -71 | 31 | 40 |
30 Sep 20 | 0 | -68 | 26 | 43 |
30 Jun 20 | 0 | -63 | 21 | 43 |
31 Mar 20 | 0 | -58 | 18 | 43 |
31 Dec 19 | 0 | -46 | 14 | 34 |
30 Sep 19 | 0 | -30 | 9 | 22 |
30 Jun 19 | 0 | -25 | 6 | 20 |
31 Mar 19 | 0 | -17 | 4 | 14 |
31 Dec 18 | 0 | -17 | 3 | 14 |
Quality Earnings: OYST is currently unprofitable.
Growing Profit Margin: OYST is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OYST is unprofitable, and losses have increased over the past 5 years at a rate of 45.9% per year.
Accelerating Growth: Unable to compare OYST's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OYST is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (53%).
Return on Equity
High ROE: OYST's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.